Drug-Coated Balloons: How Should We Incorporate Into Our Practice in Treating Superficial Femoral Artery Lesions?

Current Treatment Options in Cardiovascular Medicine

Volumn 17, Issue 5, 2015, Pages

  Zeller, Thomas ^a   Rastan, Aljoscha ^a   Macharzina, Roland ^a   Beschorner, Ulrich ^a   Noory, Elias ^a  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

Author keywords

Angioplasty; Drug eluting balloon; Drug coated balloon; Paclitaxel; Peripheral artery disease; Superficial femoral artery

Indexed keywords

ATHERECTOMY; BYPASS SURGERY; CARDIOVASCULAR EQUIPMENT; DRUG COATED BALLOON; DRUG COATING; DRUG ELUTING STENT; EVIDENCE BASED PRACTICE; FOLLOW UP; HEALTH CARE COST; HUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY BALLOON; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SILVERHAWK; SUPERFICIAL FEMORAL ARTERY; SUPERFICIAL FEMORAL ARTERY DISEASE;

EID: 84925358060     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-015-0380-3     Document Type: Review

References (37)

1. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease. Int Angiol. 2007;26:81–157.
2. Beschorner U, Sixt S, Schwarzwälder U, et al. Recanalization of chronic occlusions of the superficial femoral artery using the outback™ re-entry catheter: a single centre experience. Catheter Cardiovasc Interv. 2009;74:934–8.
3. Johnston KW. Femoral and popliteal arteries: reanalysis of results of balloon angioplasty. Radiology. 1992;183:767–71.
4. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879–88.
5. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689–99.
6. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358–65.
7. Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831–40.
8. Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7:10–9.
9. Scheinert D, Schulte KL, Zeller T, Lammer J, Tepe G. Novel paclitaxel releasing balloon in femoropopliteal lesions: 12-month evidence from the BIOLUX P-I randomized trial. JEVT 2014, in press.
10. Micari A, Cioppa A, Vadalà G, Castriota F, Liso A, Marchese A, et al. Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry. JACC Cardiovasc Interv. 2012;5:331–8.
11. Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, Metzger C, Scheinert D, Zeller T Cohen DJ, Snead DB, Alexander B, Landini M, Jaff MR for the IN.PACT SFA Trial Investigators. Drug-Coated Balloon versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and/or Popliteal Peripheral Artery Disease: 12-month Results from the IN.PACT SFA Randomized Trial. Circulation 2015;131(5):495-502. IN.PACT SFA is the to date largest and most robust published trial demonstrating a clear technical and clinical benefit up to 1 year for the treatment of femoro-popliteal artery disease using DCB.
12. Fanelli F, Cannavale A, Gazzetti M, Lucatelli P, Wlderk A, Cirelli C, et al. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol. 2014;37(4):898–907. An important study about the main limitation of DCB use in femoro-popliteal lesions.
13. Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, detection and clinical implications. Catheter Cardiovasc Interv. 2014;83:E212–220.
14. Lanzer P, Böhm M, Sorribas V, Thiriet M, Janzen J, Zeller T, et al. Mönckeberg’s media sclerosis; a non-inflammatory vascular calcification disorder. EHJ. 2014;35:1515–25. The most comprehensive review of current data concerning mediacacinosis, one potential limitation of DCB use.
15. Zeller T, Baumgartner I, Scheinert D, Brodmann M, Bosiers M, Micari A, et al. IN.PACT DEEP trial investigators. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014;64:1568–76. IN.PACT deep is to date the largest DCB trial evaluating the performance of DCB in infra-popliteal intervention in a CLI population.
16. Schnorr B, Kelsch B, Cremers B, Clever YP, Speck U, Scheller B. Paclitaxel-coated balloons - Survey of preclinical data. Minerva Cardioangiol. 2010;58(5):567–82.
17. Schnorr B, Albrecht T. Drug-coated balloons and their place in treating peripheral arterial disease. Expert Rev Med Devices. 2013;10(1):105–14.
18. Cassese S, Byrne RA, Ott I, Ndrepepa G, Nerad M, Kastrati A, et al. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials. Circ Cardiovasc Interv. 2012;5:582–9.
19. Tepe G, Zeller T, Schnorr B, Claussen CD, Beschorner U, Brechtel K, et al. High-grade, non-flow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: an additional analysis from the THUNDER study. J Endovasc Ther. 2013;20:792–800.
20. Tepe G; Schnorr B; Albrecht T; Brechtel K; Claussen CD; Scheller B; Speck U; Zeller T. Five-year follow-up data of the Thunder trial: angioplasty of femoro-popliteal arteries with drug-coated balloons. JACC Cardiovasc Interv 2014, in press.
21. Endorsed by: the European Stroke Organisation (ESO), Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clément D, Collet JP, Cremonesi A, De Carlo M, Erbel R, Fowkes FG, Heras M, Kownator S, Minar E, Ostergren J, Poldermans D, Riambau V, Roffi M, Röther J, Sievert H, van Sambeek M, Zeller T; ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). European Heart Journal 2011;32:2851–2906. The ESC guidelines on the treatment of peripheral artery disease are the most recent by a cardiovascular society published international guidelines.
22. Zeller T, Rastan A, Macharzina R, Tepe G, Kaspar M, Chavarria J, et al. Drug eluting balloons vs. drug eluting stents in long femoropopliteal lesions – a retrospective propensity score analysis. J Endovasc Ther. 2014;21:359–68.
23. Bosiers M, Torsello G, Gissler H-M, Ruef J, Müller-Hülsbeck S, Jahnke T, et al. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther. 2009;16:261–9.
24. Krankenberg H, Schlüter M, Steinkamp HJ, Bürgelin K, Scheinert D, Schulte KL, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007;116:285–92.
25. Dick P, Sabeti S, Mlekusch W, Schlager O, Amighi J, Haumer M, et al. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience. Radiology. 2008;248:297–302.
26. Stabile E, Virga V, Salemme L, Cioppa A, Ambrosini V, Sorropago G, et al. Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis. J Am Coll Cardiol. 2012;60:1739–42.
27. Virga V, Stabile E, Biamino G, Salemme L, Cioppa A, Giugliano G, et al. Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up. JACC Cardiovasc Interv. 2014;7:411–5.
28. Kitrou P, Parthipun A, Diamantopoulos A, Padayachee S, Karunanithy N, Ahmed I, et al. Paclitaxel-coated balloons for failing peripheral bypass grafts: the BYPACS study. J Cardiovasc Surg (Torino). 2014;55:217–24.
29. McKinsey JF, Zeller T, Rocha-Singh KJ, Jaff MR, Garcia LA, DEFINITIVE LE Investigators. Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. JACC Cardiovasc Interv. 2014;7:923–33. DEFINITIVE LE ist to date the largest independently controlled trial investigating the performance of atherectomy in the entire infra-inguinal vessel territory.
30. Sixt S, Carpio Cancino OG, Treszl A, Beschorner U, Macharzina R, Rastan A, et al. Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries. J Vasc Surg. 2013;58:682–6.
31. Cioppa A, Stabile E, Popusoi G, Salemme L, Cota L, Pucciarelli A, et al. Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and a paclitaxel coated balloon: one-year single centre clinical results. Cardiovasc Revasc Med. 2012;13:219–23.
32. Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation. 2011;124:17–23.
33. Inglis SC, Lewsey JD, Lowe GDO, Jhund P, Gillies M, Stewart S, et al. Angina and intermittent claudication in 7403 participants of the 2003 Scottish Health Survey: impact on general and mental health, quality of life and five-year mortality. Int J Cardiol. 2013;167:2149–55.
34. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329–40. The most recent overview about the epidemiology of PAD.
35. Pietzsch JB, Geisler BP, Garner AM, Zeller T, Jaff MR. Economic analysis of endovascular interventions for femoropopliteal arterial disease: a systematic review and budget impact model for the United States and Germany. Catheter Cardiovasc Interv. 2014;84:546–54. The most robust cost evaluation of the main stream peripheral interventional techniques in the most relevant global markets, the US and Germany.
36. Diehm N, Schneider H. Cost-effectiveness analysis of paclitaxel-coated balloons for endovascular therapy of femoropopliteal arterial obstructions. J Endovasc Ther. 2013;20:819–25.
37. Kearns BC, Michaels JA, Stevenson MD, Thomas SM. Cost-effectiveness analysis of enhancements to angioplasty for infrainguinal arterial disease. Br J Surg. 2013;100:1180–8.